Establishment of Japan high grade meningioma consortium for analysis of pathogenesis and development of new treatment strategy (JHMC)

Yoshifumi Bekku0 个研究点目标入组 200 人开始时间: 待定最近更新: 2023年11月25日

适应症

试验速览

暂无简介。

•Patients with recurrent WHO grade 1 meningioma or WHO grade 2/3 meningioma who have undergone surgical resection at participating institutions from 2001 to the start of this study , who have completed the necessary medical examinations, whose residual specimens are stored, and who have already given consent for use in medical research in general, including genetic analysis, are included in this study.
•The patients who have already given consent for the use of their specimens for genetic analysis and other medical research are also included in the study.
•In addition, patients with newly diagnosed recurrent WHO grade 1 meningioma or WHO grade 2/3 meningioma who have undergone resection after the start of this study at the participating institutions are included if their consent for use in this study has been obtained at each institution for the remaining specimens after all necessary tests for treatment have been performed. Blood samples will also be collected from patients who fall into any of the above categories and who consent to have their blood samples collected.

•Patients for whom consent for participation in the study described in "
•Methods of Obtaining Subjects' Understanding and Consent" in the research protocol can not be obtained are excluded.

recurrence, follow-up period

未报告次要终点

发起方

Yoshifumi Bekku